Related Experiment Video
Updated: Jul 28, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia
Magali Saez-Ayala1, Laurent Hoffer2,3, Sébastien Abel2
1Centre de Recherche en Cancérologie de Marseille (CRCM), CNRS, INSERM, Aix-Marseille Univ, Institut Paoli-Calmettes, Marseille, France. magali.saez-ayala@inserm.fr.
Abstract:
Cancer cells utilize the main de novo pathway and the alternative salvage pathway for deoxyribonucleotide biosynthesis to achieve adequate nucleotide pools. Deoxycytidine kinase is the rate-limiting enzyme of the salvage pathway and it has recently emerged as a target for anti-proliferative therapies for cancers where it is essential. Here, we present the development of a potent inhibitor applying an iterative multidisciplinary approach, which relies on computational design coupled with experimental evaluations. This strategy allows an acceleration of the hit-to-lead process by gradually implementing key chemical modifications to increase affinity and activity. Our lead compound, OR0642, is more than 1000 times more potent than its initial parent compound, masitinib, previously identified from a drug repositioning approach. OR0642 in combination with a physiological inhibitor of the de novo pathway doubled the survival rate in a human T-cell acute lymphoblastic leukemia patient-derived xenograft mouse model, demonstrating the proof-of-concept of this drug design strategy.
Insights
Researchers developed a potent deoxycytidine kinase inhibitor, OR0642, using computational design. This new drug, combined with a de novo pathway inhibitor, significantly improved survival rates in leukemia mouse models.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Cancer cells require deoxyribonucleotides for proliferation, utilizing both de novo and salvage pathways.
- Deoxycytidine kinase, a key enzyme in the salvage pathway, is a validated target for anti-cancer therapies.
Purpose of the Study:
- To develop a potent deoxycytidine kinase inhibitor using an iterative, multidisciplinary approach.
- To evaluate the efficacy of the lead compound in combination therapy for leukemia.
Main Methods:
- Employed computational design and experimental validation for iterative drug development.
- Assessed compound potency and activity through chemical modifications.
- Tested the lead compound, OR0642, in combination with a de novo pathway inhibitor in a leukemia xenograft model.
Main Results:
- Developed OR0642, a deoxycytidine kinase inhibitor over 1000 times more potent than masitinib.
- OR0642 combined with a de novo pathway inhibitor doubled survival rates in a human T-cell acute lymphoblastic leukemia xenograft model.
Conclusions:
- The iterative computational and experimental approach successfully accelerated drug development.
- Combined inhibition of deoxycytidine kinase and the de novo pathway shows significant therapeutic potential for leukemia.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:26Drug Discovery: Overview